Announcements
Members
Navigating the clinical ctDNA testing landscape: Assays, applications & approvals throughout the cancer patient journey
Are you new to ctDNA testing strategies? Fear not! With this walk-through, we will guide you through some high-level concepts to help orient yourself in the current clinical landscape.
VB04 - Let's interpret some variants (1)
In this briefing, we walk you through a step-by-step process of the resources you can access to assess variant pathogenicity and actionability.
Members
Understanding and estimating tumor fraction from plasma cell-free DNA
Vessel Tutorial - Understanding liquid biopsy results is highly dependent on tumor fraction of the cell-free DNA sample. Without information about ctDNA content from plasma, variant allele frequencies and uninformative testing results are very difficult to interpret.
Members
VB03 - Getting to know HRD testing
Brief Synopsis For this Briefing, we asked Prof. Ellen Heitzer and Georgios Vlachos from the Institute of Human Genetics, Medical University of...
Members
VB02 - Concordance of genomic results between tissue and liquid testing
Tissue and circulating tumor DNA testing can detect cancer alterations, but discrepancies in results can impact treatment decisions. This briefing discusses the basics and presents case studies.